Free. Unsubscribe any time.
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. filed 44 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 5 reporting owners, covering 76 transactions and 771,511 shares. 1 carry the SEC's AFF10B5ONE flag; 43 name a plan only in a footnote. 8 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-09-10, came 29 days after the one before it (2026-08-12) and reports 4 transactions against 3 in the filing before it.
- The sales it reports total 17,500 shares, 5,000 more than the 12,500 in the filing before it.
- Its 44 plan statements rank 124th of the 483 companies the register carries in Delaware, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 2 have more plan statements on file than it and 8 have fewer.
- Its 44 filings on file run from 2025-03-18 to 2026-09-10, and state 4 plan adoption dates, from 2024-11-13 to 2026-03-31.
Trades in Bicara Therapeutics Inc. 76
- Meisner Lara — 2025-03-14 · S · 48,526 shares
- Meisner Lara — 2025-03-14 · S · 30,620 shares
- Meisner Lara — 2025-06-16 · S · 15,829 shares
- Meisner Lara — 2025-09-15 · S · 15,829 shares
- Meisner Lara — 2025-09-29 · S · 33,807 shares
- Cohlhepp Ryan — 2025-10-06 · S · 24,000 shares
- Cohlhepp Ryan — 2025-10-06 · S · 15,600 shares
- Hyep Ivan — 2025-10-06 · S · 6,514 shares
- Cohlhepp Ryan — 2025-10-07 · S · 8,000 shares
- Cohlhepp Ryan — 2025-10-07 · S · 2,900 shares
- Hyep Ivan — 2025-10-07 · S · 18,244 shares
- Hyep Ivan — 2025-10-08 · S · 5,627 shares
Adoption dates in Bicara Therapeutics Inc. 4
- 2024-11-13 — stated in 4 filings
- 2025-02-12 — stated in 24 filings
- 2025-02-13 — stated in 9 filings
- 2026-03-31 — stated in 7 filings
Results prints in Bicara Therapeutics Inc. 8
- 2025-03-27
- 2025-05-13
- 2025-08-12
- 2025-11-10
- 2026-02-26
- 2026-03-30
- 2026-05-11
- 2026-08-11
Trades before a print in Bicara Therapeutics Inc. 6
- 1 day before the 2026-02-26 print — 2026-02-25 · S · Cohlhepp Ryan · 3,108 shares
- 1 day before the 2026-02-26 print — 2026-02-25 · S · Cohlhepp Ryan · 523 shares
- 1 day before the 2026-08-11 print — 2026-08-10 · S · Cohlhepp Ryan · 18,750 shares
- 1 day before the 2026-08-11 print — 2026-08-10 · S · Hyep Ivan · 12,500 shares
- 1 day before the 2026-08-11 print — 2026-08-10 · S · Mazumdar Claire · 10,000 shares
- 5 days before the 2026-03-30 print — 2026-03-25 · S · Raben David · 5,500 shares
- 7 days before the 2026-03-30 print — 2026-03-23 · S · Hyep Ivan · 9,200 shares
- 10 days before the 2026-03-30 print — 2026-03-20 · S · Mazumdar Claire · 1,596 shares
- 11 days before the 2026-03-30 print — 2026-03-19 · S · Mazumdar Claire · 6,905 shares
- 12 days before the 2026-03-30 print — 2026-03-18 · S · Mazumdar Claire · 6,499 shares
- 13 days before the 2025-03-27 print — 2025-03-14 · S · Meisner Lara · 48,526 shares
- 13 days before the 2025-03-27 print — 2025-03-14 · S · Meisner Lara · 30,620 shares
Interval to Bicara Therapeutics Inc.’s next reported results date
How the interval and sources are counted →
- 6within 5 days
- 8within 10 days
- 1shortest, days
- 2no later print
- Cohlhepp Ryan 2026-02-25 · S · 1 day before the 2026-02-26 print · President and COO
- Cohlhepp Ryan 2026-02-25 · S · 1 day before the 2026-02-26 print · President and COO
- Mazumdar Claire 2026-03-20 · S · 10 days before the 2026-03-30 print · Chief Executive Officer
- Hyep Ivan 2026-03-23 · S · 7 days before the 2026-03-30 print · Chief Financial Officer
- Raben David 2026-03-25 · S · 5 days before the 2026-03-30 print · Chief Medical Officer
- Cohlhepp Ryan 2026-08-10 · S · 1 day before the 2026-08-11 print · President and COO
- Hyep Ivan 2026-08-10 · S · 1 day before the 2026-08-11 print · Chief Financial Officer
- Mazumdar Claire 2026-08-10 · S · 1 day before the 2026-08-11 print · Chief Executive Officer
Adoption dates Bicara Therapeutics Inc. states
- 2024-11-13 in 4 filings
- 2025-02-12 in 24 filings
- 2025-02-13 in 9 filings
- 2026-03-31 in 7 filings
Filing text: “10b5-1 trading plan adopted on November 13, 2024”
Reported results dates on file
- 2025-03-27
- 2025-05-13
- 2025-08-12
- 2025-11-10
- 2026-02-26
- 2026-03-30
- 2026-05-11
- 2026-08-11
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.